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Abstract
Maresin Conjugates in Tissue Regeneration 1 (MCTR1) is a newly identified mac-
rophage-derived sulfido-conjugated mediator that stimulates the resolution of in-
flammation. This study assessed the role of MCTR1 in alveolar fluid clearance (AFC) 
in a rat model of acute lung injury (ALI) induced by lipopolysaccharide (LPS). Rats 
were intravenously injected with MCTR1 at a dose of 200 ng/rat, 8 hours after ad-
ministration of 14 mg/kg LPS. The level of AFC was then determined in live rats. 
Primary rat ATII (Alveolar Type II) epithelial cells were also treated with MCTR1 
(100 nmol/L) in a culture medium containing LPS for 8 hours. MCTR1 treatment im-
proved AFC (18.85 ± 2.07 vs 10.11 ± 1.08, P < .0001) and ameliorated ALI in rats. 
MCTR1 also significantly promoted AFC by up-regulating epithelial sodium channel 
(ENaC) and Na+-K+-adenosine triphosphatase (Na, K-ATPase) expressions in vivo. 
MCTR1 also activated Na, K-ATPase and elevated phosphorylated-Akt (P-Akt) by 
up-regulating the expression of phosphorylated Nedd4-2 (P-Nedd4-2) in vivo and 
in vitro. However, BOC-2 (ALX inhibitor), KH7 (cAMP inhibitor) and LY294002 (PI3K 
inhibitor) abrogated the improved AFC induced by MCTR1. Based on the findings of 
this study, MCTR1 may be a novel therapeutic approach to improve reabsorption of 
pulmonary oedema during ALI/acute respiratory distress syndrome (ARDS).
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1  | INTRODUC TION
Acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) 
is a life-threatening clinical condition. It damages the alveolar epithe-
lial tissues leading to non-cardiogenic pulmonary oedema.1,2 Recent 
pathophysiological advancements of ALI/ARDS have improved its 
clinical outcome.3 However, effective management and treatment of 
ALI/ARDS are challenging. As such, it has significantly high morbid-
ity and mortality rates.4,5 Previous studies report that the majority 
of ALI/ARDS patients have impaired alveolar fluid clearance (AFC).6 
Early control of increased alveolar fluid is therefore important for 
proper clinical prognosis of ALI/ARDS.
Alveolar fluid clearance is pegged on the active transport of so-
dium ions (Na+) across the alveolar epithelium via the apical alveolar 
epithelial sodium channel (ENaC) and basolateral Na+-K+-adenosine 
triphosphatase (Na, K-ATPase).7,8 ENaC is the primary driving force 
for removal of lung fluid.6 Na, K-ATPase plays the role of sodium 
pump that works in concert with apical ENaC in regulating AFC.7 
A2B adenosine receptor agonists, angiotensin, tri-Iodo-L-thyronine 
and oestradiol have exhibited increasing AFC effects via promot-
ing ENaC or Na, K-ATPase activity in animal studies.9-12 However, 
these studies remain unsuccessful in humans.9-12 Previously, we re-
ported that administration of a β-agonist salbutamol (iv) decreased 
extravascular pulmonary fluid in ALI/ARDS patients. However, some 
side-effects of salbutamol such as lactic acidosis, arrhythmia and 
tachycardia were significantly up-regulated in a 28-day mortality 
rate in a multi-centred randomized controlled clinical trial.13 This ne-
cessitated the need to identify a new therapeutic approach.
Maresin Conjugates in Tissue Regeneration 1 (MCTR1) is a spe-
cialized family of macrophage-derived sulfido-conjugated mediators. It 
possesses organ protective function as well as the ability to enhance the 
resolution of inflammation in vivo.14,15 MCTR1 (50 ng/mouse, IP) de-
creased the neutrophil infiltration and duration of resolving inflamma-
tion in mice pre-treated with lipopolysaccharide (LPS). It also enhanced 
the phagocytosis of E Coli by macrophages.16 Levy BD et al17 reported 
that MCTRs improved the recovery of the allergic airway responses in 
mice. However, the effects of MCTR1 on AFC are yet to be explored.
In this study, the beneficial effects of MCTR1 on AFC in ALI 
caused by LPS treatment were explored. Moreover, the effects of 
MCTR1 on levels of phosphorylated-Akt (P-Akt), Na, K-ATPase, 
ENaC and phosphorylated Nedd4-2 (P-Nedd 4-2) in the rat lungs and 
alveolar type II (ATII) cells were explored. Furthermore, the signal-
ling pathways of MCTR1 were studied to assess its response to ALX 
receptor inhibitor (BOC-2), cAMP inhibitor (KH7), PI3K antagonist 
(LY294002) and PKA blocker (H89) on AFC.
2  | MATERIAL S AND METHODS
2.1 | Reagents
MCTR1 (Item No. 17007) was sourced from Cayman Chemical 
Company. It was stored at −80°C before use. LPS (Escherichia coli 
serotype 055: B5, L2880) was procured from Sigma. KH7 (cAMP in-
hibitor, HY-103194), H89 (PKA inhibitor, HY-15979A) and LY294002 
(PI3K inhibitor, HY-10108) were obtained from MedChemExpress. 
Further to this, Cyclic AMP (cAMP, BP-E30574) ELISA kits, 
Interleukin-1 (IL-1, BP-E30419), Interleukin-10 (IL-10, BP-E30651), 
myeloperoxidase (MPO, BP-E30262) and tumour necrosis factor 
(TNF-α, BP-E30635) were procured from R&D Systems. The ALX 
inhibitor BOC-2(RP12950) was purchased from Biomol-Enzo Life 
Sciences. The anti-Na channel α (orb101489), β (orb67568) and γ 
(orb389322) antibodies were procured from Biorbyt (Cambridge, 
Cambridge shire) while Anti-Na, K-ATPase α1 (ab7671) and β1 
(ab193669) antibodies were procured from Abcam. Total Akt 
(T-Akt, 4691), Anti-Phosphorylated-Akt (P-Akt, 4060) and Anti-
Phosphorylated-Nedd4-2 (P-Nedd4-2, 8063) antibodies were ob-
tained from Cell Signalling Technology.
2.2 | Experimental animals
All the experiments were performed using adult male Sprague-
Dawley (SD) rats weighing between 250 and 300 g. The rats were 
procured from SLAC Laboratory Animal (Shanghai Experimental 
Animal Centre of China). The experiments were approved by the 
Animal Studies Ethics Committee of the Second Affiliated Hospital 
of Wenzhou Medical University.
The rats were randomly divided into nine groups each compris-
ing seven rats. The nine groups were as follows: a control group, 
LPS group, LPS+MCTR1 group, MCTR1 group, LPS+MCTR1+BOC-2 
group, LPS+MCTR1+KH7 group, LPS+MCTR1+H89 group, 
LPS+MCTR1+LY294002 group and LPS+MCTR1+DMSO group. Rats 
in the LPS group were injected with 14 mg/kg of LPS via the caudal 
vein to create the LPS-induced lung injury model. The control and 
MCTR1 models were constructed by intravenous administration of 
200 ng of 0.9% saline or an equal volume of MCTR1, respectively. 
Rats in the LPS+MCTR1 group were first injected with LPS via the 
caudal vein and then with MCTR1 (200 ng/rat) after 8 hours. For 
the LPS+MCTR1+BOC-2, LPS+MCTR1+KH7, LPS+MCTR1+H89, 
LPS+MCTR1+LY294002 and LPS+MCTR1+DMSO groups, the ex-
perimental rats were injected with BOC-2, 1 mg/kg KH7, 1 mg/kg 
H89, or 3 mg/kg LY294002 and DMSO, respectively. This was done 
8 hours post-LPS injection and 30 minutes pre-MCTR1 (200 ng/rat) 
administration, respectively. Prior to placement of a tracheotomy 
tube, the rats were anaesthetized by administration of 3% pento-
barbital sodium (30 mg/kg) intraperitoneally. The rats received sus-
tained mechanical ventilation for 1 hour. They were then killed and 
the chest opened to harvest the lungs.
2.3 | Pulmonary histopathology evaluation
The left lung tissues of the killed rats from each group were fixed in 
4% paraformaldehyde for 24 hours. This was done for light micros-
copy analysis. Subsequently, the fixed lung tissues were embedded 
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in liquid paraffin and stained with haematoxylin and eosin (H&E). 
Lung injury scores were determined by a semi-quantitative scoring 
system based on several indicators.18 The indicators were as follows: 
alveolar congestions, alveolar haemorrhage, infiltration of neutro-
phils, thickness of the alveolar wall/hyaline membrane, aggregation 
in the airspace or vessel wall and infiltration of inflammatory cells. 
Light microscopy pathologic findings were graded between 0 and 4. 
A score of 4 represented very severe injury of the lung tissue (almost 
100%), 3 represented severe injury (75%), 2 represented moderate 
injury (50%), 1 represented slight injury (25%) while 0 represented 
no injury. The sum of the four variables represented the lung injury 
score (total score: 0-16).
2.4 | ELISA
The right lung tissues from each group were homogenized and cen-
trifuged as per the manufacturer's guidelines. The R&D systems 
ELISA kits were then used to determine the concentrations of MPO, 
IL-10, TNF-α and IL-1β in the supernatants.
2.5 | Transmission electron microscopy
Harvested lung tissue blocks were incubated in 0.1 mol/L phosphate 
buffer (350 mOsm, pH 7.4) for 24 hours. The blocks were then fixed 
in osmium tetroxide (1% osmium tetroxide in 0.125 sodium caco-
dylate buffer; 400 mOsm, pH 7.4) for 2 hours. The tissues were 
subsequently dehydrated in graded ethanol (50%-100%), rinsed in 
propylene oxide and embedded in Araldite. Thereafter, the tissue 
blocks were sliced into ultrathin sections (50-70 nm) and stained 
with saturated uranyl acetate and bismuth subnitrate. The sections 
were then viewed under a Zeiss EM 10C transmission electron mi-
croscope (HITACHI, H-7500, Abcam). Images were obtained for the 
carbon grating replica to facilitate calibration.
2.6 | Measurement of alveolar fluid clearance in 
live rats
Alveolar fluid clearance is expressed as percentage of the total in-
stilled volume cleared within 60 minutes. Alveolar fluid clearance 
was determined based on concentration changes in the Evan's blue-
tagged-albumin as previously described by our laboratory.18
For alveolar instillation, 50 mg/mL BSA was dissolved in modi-
fied lactated Ringer's solution (137 mmol/L NaCl, 4.67 mmol/L KCl, 
1.82 mmol/L CaCl2·2H2O, 1.25 mmol/L MgSO4·7H2O, 5.55 mmol/L 
dextrose and 12 mmol/L HEPES) to a final concentration of 5% BSA 
of pH 3.0-7.4 at 7°C. This solution was labelled with 0.15 mg/mL 
Evans blue. The rats were anaesthetized with 3% pentobarbital so-
dium (30 mg/kg, IP) and a polyethene endotracheal tube inserted. 
The tube was then connected to a constant volume ventilator (model 
HX-300 Animal Ventilator; Taimeng Company of Chengdu) with an 
oxygen inspiration fraction of 35%. A 4.5 mL tidal volume was main-
tained and the respiratory rate of the rats adjusted to 50 breaths/
min. The positive end-expiratory pressure was maintained at 2 cm 
H2O during the baseline period. The rats stabilized for 10 minutes 
after tracheostomy. Subsequently, the animals were placed in the 
left lateral decubitus position, and an instillation tube (16G epidural 
catheter) gently passed through the tracheostomy tube into the left 
lung. 1.5 mL (5 mL/kg) of albumin solution was then instilled at a 
rate of 0.08 mL/min using a syringe pump. Thereafter, all the liquid 
in the instillation catheter was cleared by injecting 0.2 mL of air. The 
albumin solution remaining in the syringe was collected as the initial 
sample. The catheter was left in place for 60 minutes after instilla-
tion. The final alveolar sample was also collected via the instillation 
catheter. The concentration of Evan's blue-tagged albumin in the 
instilled and aspirated solutions was then determined using a spec-
trophotometer at a wavelength of 621nm. AFC was then calculated 
using the equation: alveolar fluid clearance = (1 − C0/C1), where C1 
represented the protein concentration o of the sample collected 
after 60 minutes of mechanical ventilation whereas C0 represented 
the protein concentration of the albumin solution before instillation.
2.7 | Extraction and preparation of primary rat 
ATII cells
Lung tissues were digested using elastase digestion and differen-
tially adhered to IgG-coated plates as described by Dobbs et al19 
The purity of ATII cells was then determined using the modified 
Papanicolaou stain by identifying the presence of dark blue inclu-
sions. The trypan blue exclusion assay was used to evaluate ATII 
cell viability (>95%). ATII cells were seeded on plastic dishes con-
taining Dulbecco's modified Eagle's medium (DMEM) supplemented 
with 10% foetal bovine serum, 0.1 mg/mL streptomycin, 100 U/mL 
penicillin and 2 mmol/L l-glutamine at a density of 1 × 106 per cm2. 
The cells were cultured in 5% CO2 and 95% air in six-well plates and 
grown to 80% confluence. The cells were subsequently deprived of 
serum for 24 hours after which 1 μg/mL LPS was added in the pres-
ence or absence of MCTR1 (100 nmol/L).
2.8 | Western blot analysis
Protein extraction was done using RIPA lysis buffer (50 mmol/L 
Tris [pH 7.4], 0.1% sodium-dodecyl sulphonate, 1% sodium de-
oxycholate, 150 mmol/L NaCl, 1% Triton X-100, sodium fluoride 
sodium orthovanadate, leupeptin and ethylene-diamine-tetra ace-
tic acid) and phenyl-methane-sulfonyl fluoride. The samples were 
then ultrasonicated thrice for 5 seconds followed by centrifuga-
tion for 30 min at 12 000 g RCF. The BCA assay (Thermo Scientific) 
was then used to quantify the proteins. Proteins were then re-
solved on a 10% sodium-dodecyl sulphonate polyacrylamide gel 
and the bands transferred onto polyvinylidene fluoride (PVDF) 
membranes. The membranes were blocked with 5% non-fat milk 
4  |     HAN et Al.
in TBS containing 0.05% Tween-20 followed by overnight incuba-
tion with primary antibodies at 4°C. The primary antibodies used 
were as follows: sodium channel α, β and γ (1:1000), Na, K-ATPase 
α1 and β1 (1:1000), β-actin (internal control, 1:1000), Akt (1:2000), 
P-Akt (1:2000) and P-Nedd4-2 (1:1000). The membranes were 
then incubated with HRP-conjugated secondary antibodies 
(1:3000; Santa Cruz Company) at room temperature for 1 hour. 
Electrochemiluminescence (ECL) was then used to detect the pro-
tein bands while band visualization was done using a UVP gel im-
aging system (Upland, CA). AlphaEaseFC (version 4.0) was used to 
analyse the band intensities.
2.9 | Confocal imaging
ATII cells were incubated with MCTR1 (100 nmol/L), saline, LPS 
(1 μg/mL) or LPS+MCTR1 for 8 hours. This was followed by fixa-
tion in 4% paraformaldehyde and blocking with 10% donkey serum 
in PBS. The cells were then incubated in a solution containing rabbit 
anti-sodium channel α antibodies (1:50) and monoclonal mouse anti-
Na, K-ATPase α1 (1:200 dilution) at 4°C for 16 hours. Thereafter, 
they were incubated with donkey antimouse IgG (1:150) and Alexa 
Fluor donkey anti-rabbit (1:250) antibodies at 37°C for 1hour. Finally, 
the cells were viewed under a confocal laser-scanning microscope 
(Leica) and analysed using the ImagePro plus 6.3 software (Media 
Cybernetics).
2.10 | Measurement of Na, K-ATPase activity in rat 
lung tissues
The ouabain-sensitive ATP hydrolysis was used to assess the hydro-
lytic activity of Na, K-ATPase under maximal velocity conditions. 
Lung tissues were harvested and processed by centrifugation and 
homogenization. The activity of Na, K-ATPase was then measured 
using the minimal ATP enzyme test kit (Jian Cheng Company) follow-
ing the manufacturer's instructions.
2.11 | Measurement of cAMP concentrations
Isobutyryl methylxanthine (Sigma-Aldrich) was added to the cells to 
suppress phosphodiesterase. The cells were then homogenized in 
ice-cold 1 mol/L TCA and centrifuged at 2500 g RCF to precipitate 
the cells. The cAMP ELISA kit (R&D Systems) was then used to de-
termine the concentration of cAMP in the lysates.
2.12 | Blinding method
A completely randomized design was adopted in the blinding of 
patient. The SAS/STAT software was used to generate a rand-
omization list. The separation function was employed to achieve 
blinding. One researcher dispensed and administered treatments 
to the rat models while a different group of researchers was in-
volved in harvesting the lung tissues for Western blot, alveolar 
fluid clearance measurement, transmission electron microscopy 
and pathological examination.
2.13 | Statistical analysis
All statistical analyses were done by one-way anova using Prism 7.0 
software (GraphPad Software). All data are presented as mean ± SD. 
Mean separation was done using the Tukey's post hoc test at 95% 
confidence interval (*P < .05, **P < .01 and ***P < .001).
3  | RESULTS
3.1 | MCTR1 ameliorates LPS-Induced ALI
We assessed pathological changes in lung tissue by HE staining. 
While the lung tissues of the control group had a normal histology, 
tissues from the LPS group were substantially injured (Figure 1A,B). 
These injured tissues were characterized by haemorrhage, intersti-
tial oedema and alveolar wall thickening. Inflammatory cell infiltra-
tion into the alveolar space and the interstitium was also observed 
in the injured tissues. This was revealed by increased lung injury 
scores (Figure 1C). Tissue injuries suggested that ALI occurred in 
this model. The morphological changes were comparatively lower in 
the LPS+MCTR1 group than the LPS group. However, there was no 
significant difference between the control and the MCTR1 groups. 
This observation indicated that MCTR1 efficiently ameliorated his-
topathological changes of the lung tissues thus attenuating LPS-
induced ALI. Consistent with these histopathological observations, 
the lung injury scores in the LPS group were significantly higher 
compared to those of the control group, LPS+MCTR1 group and 
MCTR1 group (Figure 1C).
Besides, we determined the concentrations of myeloperoxidase 
(MPO), TNF-α, interleukin-1β (IL-1β) and interleukin-10 (IL-10) in 
the lung tissue homogenates using ELISA. LPS-induced increase of 
myeloperoxidase, TNF-α, IL-1β and IL-10 protein levels were signifi-
cantly decreased by MCTR1 treatment (Figure 1D-G).
3.2 | MCTR1 up-regulates the clearance of alveolar 
fluid in LPS-induced ALI
This study assessed the effect of MCTR1 on the clearance of alveo-
lar fluid in LPS-induced ALI in vivo. Experimental results indicated 
that the LPS group had a lower alveolar fluid clearance rate than the 
control group (10.11 ± 1.08 vs 25.64 ± 2.92). Notably, administration 
of MCTR1 increased alveolar fluid clearance after LPS-induced ALI 
(18.85 ± 2.07 vs 10.11 ± 1.08). However, there was no significant dif-
ference between the control and MCTR1 groups (Figure 1H).
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F I G U R E  1   MCTR1 ameliorates 
lung injury and enhances alveolar fluid 
clearance in a rat model of ALI induced 
by LPS. MCTR1 (200 ng/rat) was 
administered to Sprague-Dawley (SD) 
rats eight hours post-stimulation with LPS 
(14 mg/kg). Lung tissue sections were 
stained with haematoxylin and eosin 
(Magnification ×200, ×400) to evaluate 
the effects of MCTRI (A, B). Scores of 
lung injury (C) ranging from 0 to 16 as 
described in Section 2. Zero indicates 
no damage whereas 16 indicates the 
highest damage. Expression of MPO (D), 
TNF-α (E), IL-1β (F) and IL-10 (G) in lung 
tissues determined using ELISA. Following 
intratracheal instillation with 5% of 
albumin solution comprising albumin 
labelled with Evans blue (5 mL/kg) via 
a left lung tracheostomy, clearance of 
alveolar fluid was measured for 60 min 
in pre-ventilated animals. (H) All data 
are presented as mean ± SD. n = 7, 
***P < .001. MCTR1, Maresin Conjugates 
in Tissue Regeneration 1; MPO, 
myeloperoxidase
F I G U R E  2   Effects of MCTR1 on ultrastructure of lung tissue in LPS-induced lung injury in vivo. MCTR1 (200 ng/rat) was administered 
to SD rats 8 h after LPS injected (14 mg/kg). Next, 60-min ventilation of the rats was performed. Photomicrographs of lung tissues taken by 
electron microscope were used to explore the effects of MCTR1. Severe vacuolation of the lamellar bodies was observed in the LPS group 
in contrast to the mock group; but, MCTR1 administration alleviated the damage to the lamellar body (A). In the mock group, the air-blood 
barrier was normal but it was damaged in the LPS group as indicated by broken capillary walls and epithelial bridges in the lung tissues. LPS 
damaged the air-blood barrier and this effect was eliminated by MCTR1 treatment (B). ac, air capillary; bc, blood capillary; cn, cell nucleus; 
ecm, extracellular matrix of the capillary wall; en, endothelial cell; ep, epithelial bridge; er, erythrocyte; lb, lamellar body
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3.3 | MCTR1 reversed the LPS-induced injury to the 
air-blood barrier
Further determination of the impact of MCTR1 on the ultrastruc-
ture of the lung tissues revealed that the samples obtained from 
rats treated with LPS showed high vacuolation of lamellar bodies 
compared to the control group. However, administration of MCTR1 
ameliorated this pathological change (Figure 2A). Notably, although 
air-blood barrier was intact in the control group, it was damaged in 
the LPS group as demonstrated by broken capillary walls and epithe-
lial bridges (Figure 2B). Therefore, MCTR1 substantially reversed the 
LPS-induced injury to the air-blood barrier.
3.4 | MCTR1 up-regulates Na, K-ATPase and sodium 
channels in LPS-induced ALI in vivo
The LPS+MCTR1 group has a higher protein expression of the α, β, γ 
sodium channel subunits and the Na, K-ATPase α1, β1 subunits com-
pared with the LPS group (Figure 3A-E). Besides this, the activity of 
the Na, K-ATPase was significantly reduced in the LPS group compared 
with the control group. However, the activity of the Na, K-ATPase was 
significantly increased by administration of MCTR1 (Figure 3F).
3.5 | MCTR1 facilitates clearance of alveolar fluid 
by activating the ALX/cAMP/PI3K/P-Nedd4-2 
pathway in vivo
This study further assessed the ALX/cAMP/PI3K/P-Nedd4-2 path-
way-dependent actions of MCTR1 in vivo by determining the con-
centrations of cAMP in the lung tissues. Experimental result revealed 
that the concentration of cAMP in the control group was higher than 
in the LPS group. cAMP concentrations were increased by MCTR1 
treatment in LPS-treated lungs (Figure 4A). Further to this, the ex-
pression levels of the Ser473-phosphorylated-Akt protein (P-Akt) 
in rat lung tissue homogenates were also assessed. The LPS group 
had significantly lower expression of the P-Akt protein compared 
with the control group. However, the P-Akt protein expression lev-
els were considerably lower in the LPS group than the LPS+MCTR1 
group (Figure 4B). Nedd 4-2 is critical for the negative control of 
Na+ transport. It is an E3 ubiquitin-protein ligase that primes the 
degradation of the protein channel. However, phosphorylation of 
Nedd4-2 by P-Akt nullifies its priming effect.20 In this study, LPS-
treated rats showed lower expression of P-Nedd4-2 compared with 
the control group. However, its expression was significantly higher in 
the MCTR1 group compared to the LPS group (Figure 4C).
We then used BOC-2 (ALX inhibitor), KH7 (cAMP inhibitor), 
LY294002 (PI3K inhibitor) and H89 (PKA inhibitor) to determine the sig-
nalling pathway. We found that alveolar fluid clearance was lower in the 
LPS+MCTR1+BOC-2 (10.68 ± 1.73), LPS+MCTR1+KH7 (11.90 ± 1.89) 
and LPS+MCTR1+LY294002 groups (10.70 ± 1.13) compared with the 
LPS+MCTR1 group (18.85 ± 2.07). However, alveolar fluid clearance 
was equal in the LPS+MCTR1+H89 and LPS+MCTR1+DMSO groups 
(18.03 ± 1.33 & 18.43 ± 0.69, respectively) (Figure 5A). Besides this, 
cAMP concentrations in the LPS+MCTR1 group were higher than that 
of LPS+MCTR1+KH7 and LPS+MCTR1+BOC-2 groups (Figure 5B). 
In addition, BOC-2, KH7 and LY294002 significantly suppressed the 
increase in P-Akt and P-Nedd 4-2 protein levels induced by MCTR1 
(Figure 5C,D). In addition, KH7, BOC-2 and LY294002 substantially 
suppressed the MCTR1-induced increase in P-Akt protein levels 
(Figure 5C). BOC-2, KH7 and LY294002 markedly suppressed the 
MCTR1-induced increases in P-Nedd 4-2 protein levels (Figure 5D).
3.6 | MCTR1 regulates Na, K-ATPase α1 
expression in primary ATII cells in a dose- and time-
dependent manner
ATII cells were incubated in different concentrations of MCTR1, that 
is 1, 10, 100 and 200 nmol/L. The expression of the α1 subunit of 
the Na, K-ATPase pump was up-regulated as the concentration of 
MCTR1 increased. The highest effects were observed at MCTR1 
concentration of 100 nmol/L (Figure 6A). Based on this observa-
tion, subsequent tests evaluated the expression level of the sodium 
channel and Na, K-ATPase pump in ATII cells at 100 nmol/L MCTR1. 
Moreover, the expression of the α1 subunit of the Na, K-ATPase in pri-
mary ATII cells was up-regulated 8 hours post MCTR1 (100 nmol/L) 
treatment (Figure 6B).
3.7 | MCTR1 up-regulated the expression of the 
Na and Na, K-ATPase pump in primary rat ATII cells
Rat primary ATII epithelial cells were incubated with MCTR1 for 
8 hours at 37°C with and without LPS. Confocal laser-scanning 
microscopy results revealed that MCTR1 increased the expression 
of sodium channel α (Figure 7A) and Na, K-ATPase α1 (Figure 7B). 
The LPS+MCTR1 group had a higher protein expression of sodium 
channel α, β, γ subunits and Na, K-ATPase α1, β1 subunits than the 
LPS group (Figure 7C-G). Consistent with the protein expression in 
lung tissue homogenates, the expression of P-Akt and P-Nedd4-2 
proteins was higher in the LPS+MCTR1 group compared to the LPS 
group in primary ATII cells. (Figure 7H,I).
4  | DISCUSSION
This study revealed that MCTR1 ameliorated lung injury and stimu-
lated AFC of LPS-induced ALI in a rat model. This led to reduction of 
lung oedema. Besides this, the study showed that MCTR1 not only 
up-regulated the in vivo and in vitro expression of ENaC and Na, 
K-ATPase proteins, but also increased Na, K-ATPase activity in vivo. 
MCTR1 also increased P-Akt and P-Nedd4-2 protein expressions 
in vivo and in vitro. ALX receptor inhibitor (BOC-2), cAMP inhibitor 
(KH7) and PI3K inhibitor (LY294002) suppressed AFC increase by 
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MCTR1. This finding suggested that MCTR1 promotes AFC in ALX/
cAMP/PI3K/P-Nedd4-2 pathway-dependent manner. The in vivo 
and in vitro effects of MCTR1 in LPS-induced ALI are presented in 
Figure 8.
ALI/ARDS exhibits increased alveolar-capillary permeability and 
impaired alveolar fluid clearance.21 The currently available thera-
pies are ineffective in modulating this inflammatory response.3 It is 
known that the clearance of alveolar oedema is vital to ALI/ARDS 
patient survival.22 In this study, we found that MCTR1 significantly 
protected the lamellar body structure and alveolar-capillary barrier 
from being damaged by LPS. Importantly, MCTR1 improved the AFC 
8 hours after treatment with LPS. Previous studies reported that ex-
cessive levels of cytokines might cause alveolar injury and impaired 
AFC.23,24 These results were consistent with those of this study. 
MCTR1 reduced the lung inflammatory cytokines such as MPO, 
TNF-α, IL-1β and IL-10. These findings proved that lung inflammatory 
cytokines are associated with severity of ALI/ARDS.25 These results 
suggest that MCTR1 promoted the resolution of inflammation in 
ALI/ARDS.
ENaC is the primary driving force of AFC. It promotes removal 
of lung fluid from alveolar spaces and thus is beneficial for man-
agement of ALI/ARDS.26 It is expressed in both ATI and ATII cells 
and is the key player in the Na+ transport system.27 The three 
homologous subunits of ENaC (Na+ channel-α, β and γ) allow the 
flow of Na+ ions through the high resistance epithelia thus en-
abling monitoring of the salt and water homeostasis in the body. 
Mice genetically lacking the Na+ channel-α, they are unable to 
clear the alveolar oedema fluid resulting to death within 40 hours 
of birth.28 MCTR1 improved the expression of Na+ channel-α, β 
and γ subunits in pulmonary tissue homogenates in LPS-induced 
ALI. It also improvised the three homologous subunits in LPS-
stimulated ATII cells. The ATII cells showed similar results on 
F I G U R E  3   MCTR1 increases sodium 
channel and Na, K-ATPase expression 
and Na, K-ATPase activity in lung injury 
induced by LPS in vivo. MCTR1 (200 ng/
rat) was administered to SD rats 8 h 
post-LPS induction (14 mg/kg); after 
which 60-min ventilation of the rats was 
carried out. Next, tissues of right lung 
were harvested and used to determine 
the protein expression levels of the α, β, 
and γ sodium channel subunits (A, B, C) 
and Na, K-ATPase α1 and β1 subunits (D, 
E) using Western blot assay. The activity 
of Na, K-ATPase in the homogenates of 
lung tissue (F). All data are presented 
as mean ± SD. n = 7, ***P < .001. 
MCTR1, Maresin Conjugates in Tissue 
Regeneration 1
F I G U R E  4   The effect of MCTR1 is partly mediated by ALX, cAMP and PI3K pathways in vivo. MCTR1 (200 ng/rat) was administered 
to SD rats 8 h post-LPS induction (14 mg/kg); after which 60-min ventilation of the rats was carried out. The right lung tissues were 
harvested and used to perform ELISA for determination of cAMP concentration (A), and Western blot to determine the protein expressions 
of phosphorylated-Akt (B) and Nedd4-2 (C). All data are presented as mean ± SD. n = 7, ***P < .001. MCTR1, Maresin Conjugates in Tissue 
Regeneration 1
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confocal LASER-scanning microscopy. It has been established that 
the up-regulation of Na+ channel aid pulmonary oedema fluid re-
absorption while down-regulation of Na+ slow down the process 
after thiourea-induced lung injury.29 As such, Na+ channel up-reg-
ulation by MCTR1 promotes AFC.
Na, K-ATPase works in concert with apical ENaC in regulating 
clearance of lung oedema.26 Na+ gain entry to the cell through either 
cationic or amiloride-sensitive Na+ channels at the apical surface 
and expelled at the basolateral surface through Na, K-ATPase. Fluid 
and solute conveyance in alveoli are severely decreased with the 
inhibition or loss of Na, K-ATPase.7 Increased Na+ transport through 
up-regulation of Na, K-ATPase and Na+ channels results in the abil-
ity to clear pulmonary oedema.21,30 Even in the preclinical stage, 
impaired Na, K-ATPase functions serve as a hallmark of pulmonary 
injury.21,31 Herein, expression of primary ATII cells and K-ATPase in 
lung tissues of the rats was enhanced by MCTR1 after being treated 
with LPS. MCTR1 promoted the clearance of alveolar fluid via the 
Na, K-ATPase and sodium channel essential mechanisms.
Generally, it is thought that the bioactions of specialized pro-re-
solving mediators (SPMs) are mediated via specific high-affinity G 
protein-coupled receptor (GPCR).32 ALX/FPR2 is a well-known 
GPCR bound by SPMs such as LXA4, RvD1 and their stable ana-
logues.33 Herein, the clearance of alveolar fluid was enhanced by 
MCTR1. However, BOC-2 (ALX antagonist) abrogated its beneficial 
effects in vivo. This was an indication that response to MCTR1 was 
partly dependent on ALX.
Up-regulation of intracellular cAMP levels is a sign of GPCRs path-
way activation. Previous studies revealed that cAMP-regulated AFC 
enhancement by activating Na+ transport and Na, K-ATPase. It is thus a 
vital mechanism in lung oedema reabsorption.29 Our previous studies 
F I G U R E  5   Inhibition of ALX, cAMP and PI3K pathways 
decreases the role of MCTR1 on AFC in vivo. BOC-2 (600 ng/
kg, ALX receptor inhibitor), KH7 (1 mg/kg, cAMP inhibitor), 
H89 (1 mg/kg, PKA inhibitor) or LY294002 (3 mg/kg, PI3K 
inhibitor) were administered to SD rats 30 min prior to MCTR1 
administration (200 ng/rat). Subsequently, we inoculated 5% 
albumin solution comprising albumin tagged with Evans blue 
(5 mL/kg) into intratracheal of rats via the left lung tracheostomy 
to determine AFC (A). Lung tissues were then harvested and used 
to perform ELISA for determination of cAMP concentration (B), 
also for Western blot to determine expression levels of P-Akt (C) 
and P-Nedd4-2 (D). All data are presented as mean ± SD. n = 7, 
***P < .001, **P < .01. *P < .05. MCTR1, Maresin Conjugates in 
Tissue Regeneration 1
F I G U R E  6   MCTR1 regulates the expression of Na, K-ATPase in 
primary ATII cells in a time and dose-dependent manner. Western 
blot assay was used to explore how LPS (1 μg/mL) affects the 
expression level of Na, K-ATPase in primary ATII cells. Cells were 
treated with various concentrations of MCTR1 for 8 h, including 
1 nmol/L, 10 nmol/L, 100 mol/L and 200 nmol/L and then used to 
perform Western blot (A). ATII cells were treated with LPS (1 μg/
mL) for 1, 2, 4, 8 h at 100 nmol/L MCTR1 and the expression 
levels of Na, K-ATPase α1 subunit was determined (B). All data 
are presented as mean ± SD. n = 7, ***P < .001. MCTR1, Maresin 
Conjugates in Tissue Regeneration 1
F I G U R E  7   MCTR1 enhances the expression level of sodium channel and Na, K-ATPase in primary ATII cells treated with LPS in vitro. 
Briefly, primary ATII cells from SD rats were exposed to LPS (1 μg/mL) in the presence or absence of MCTR1 (100 nmol/L) for 8 h. Thereafter, 
cells were sonicated and incubated with specific antibodies. Cells were examined with Confocal laser-scanning microscopy to detect the 
expression levels of sodium channel α (A) and Na, K-ATPase α1 (B) (original magnification ×400). Western blot assay was also performed to 
evaluate the expression level of sodium channel α, β, and γ subunit (C-E), Na, K-ATPase α1 and β1 subunit (F, G), P-Akt (H) and P-Nedd4-2 (I) in 
the cell lysates. All data are presented as mean ± SD. n = 7, ***P < .001. MCTR1, Maresin Conjugates in Tissue Regeneration 1
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demonstrated that pro-resolving mediators activated cAMP through 
ALX to promote AFC as opposed to cGMP.18,34 LPS inoculation de-
creased intracellular cAMP levels. However, MCTR1 nullified this re-
duction in vivo in the LPS group. To further confirm these results, in 
vivo application of cAMP inhibitor (KH7) was performed. Intriguingly, 
AFC was reduced by KH7 in ALI induced by LPS. This showed that 
MCTR1 could promote AFC through ALX activation of cAMP.
It is widely accepted that both PKA and PI3K can be activated by 
cAMP.35,36 PI3K signals are associated with the regulation of sodium 
channel trafficking and activity.37 PI3K also regulates clearance of al-
veolar fluid by insulin through sodium channel mediation.38 This study 
revealed that LY294002 inhibited the elevation of cAMP level through 
MCTR1 induction. Additionally, LY294002 restricted the increasing AFC 
in the MCTR1 treatment group. Akt is a critical effector kinase down-
stream of PI3K signalling pathway that influences many physiological 
processes.39 Experimental results revealed that stimulation of LPS led 
to a reduction in P-Akt (ser473). However, the reduction was attenuated 
by MCTR1 Akt (ser473). Notably, LY294002, BOC-2 and KH7 suppressed 
these effects. We therefore concluded that MCTR1 enhances AFC 
through activation of P-Akt in an ALX/ cAMP/PI3K dependent pathway.
The mechanism that underlies insulin-induced Akt regulation of 
ENaC activity involves phosphorylation of Nedd4-2.40 Lee IH et al,40 
reported that Akt increased ENaC activity by inducing Nedd4-2 
phosphorylation consequently increasing Na+ absorption. Similarly, 
we found that MCTR1 increased the expression level of P-Nedd4-2 
in the LPS group. However, the beneficial effects of MCTR1 were 
inhibited by BOC-2, LY294002 and KH7 inhibitors in vivo.
5  | CONCLUSION
Results of this study revealed that administration of MCTR1 in-
creases AFC in rat lungs injured by LPS. These findings also indicate 
that AFC is dependent on enhanced expression of Na+/K+-ATPase 
and ENaC via the ALX/cAMP/PI3K/P-Nedd4-2 signalling pathways 
following administration of MCTR1. Furthermore, the findings of 
this study reveal a new mechanism for reabsorption of pulmonary 
oedema. Evidently, MCTR1 may be a novel mediator of improving 
the “reabsorption targeted” treatments. These types of treatments 
are more precise in management of ALI/ARDS.
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F I G U R E  8   MCTR1 ameliorates acute 
lung injury induced by LPS in vitro and 
in vivo. In this study, we established the 
acute lung injury model induced by LPS 
in rats and primary ATII cells. MCTR1 
activates ALX, cAMP, PI3K, P-Akt and 
P-Nedd4-2. In addition, it increases the 
expression of ENaC and Na, K-ATPase 
thereby improve the alveolar fluid 
clearance. ATII, Alveolar Type II; LPS, 
lipopolysaccharide; MCTR1, Maresin 
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